Orasure Technologies INC: directors' dealings · United States · SEC (Form 4)

About Orasure Technologies INC

OraSure Technologies Inc. (NASDAQ: OSUR) is a U.S.-based diagnostics and sample-collection company headquartered in Bethlehem, Pennsylvania, United States. Founded in 1987 as SolarCare, the company adopted the OraSure Technologies name in 2000 when it entered the public markets. For French-speaking investors in Europe, OraSure can be viewed as a specialized healthcare tools company focused on decentralized testing, meaning diagnostics designed for use at the point of care, at home, or in near-patient settings. The business is organized around two core pillars: diagnostics and sample management solutions. In diagnostics, OraSure sells rapid tests and related devices across several clinical areas, including HIV, hepatitis C, COVID-19, syphilis, sickle cell disease, and historically Ebola. In sample management, the company provides collection and stabilization technologies that preserve DNA and RNA across multiple sample types such as saliva, oral fluid, urine, skin cells, blood, and stool. This platform is strategically important because it broadens the company’s reach into genomics research, laboratory workflows, and specialized clinical applications. From a competitive standpoint, OraSure holds a niche position in rapid diagnostics and specimen collection, with a well-recognized brand franchise around OraQuick and its collection technologies. However, the company operates in a crowded and heavily regulated market, where reimbursement dynamics, public-health funding, and regulatory approvals materially influence demand. Recent results underline that the business has been transitioning away from the pandemic-era COVID revenue spike; at the same time, the underlying core business has remained relatively more stable, with diagnostics showing year-over-year growth in early 2025 even as total revenue declined because of the sharp drop in COVID-related sales. Geographically, OraSure is anchored in Bethlehem, Pennsylvania, with additional operations through DNA Genotek in Ottawa, Canada, Sherlock Biosciences in the U.S. and the U.K., and BioMedomics in North Carolina. This footprint supports both product development and international commercialization. Recent company updates in 2025 and early 2026 highlighted management’s push to reaccelerate growth through new product milestones, including a rapid molecular self-test for Chlamydia and Gonorrhoeae and the Colli-Pee™ at-home urine collection device for sexually transmitted infection testing. Management also referenced a $40 million share repurchase program, which signals a willingness to return capital while execution improves. Overall, OraSure Technologies is a small-cap U.S. healthcare diagnostics name listed on the NASDAQ, with meaningful exposure to innovation, regulatory timing, and post-pandemic normalization. For investors monitoring SEC Form 4 insider activity, the stock can be viewed as a catalyst-driven diagnostics platform with both operational leverage and elevated execution risk.